HX4
PreclinicalSmall molecule
HX4 is one of 115 small molecule programs targeting Intestinal Cancer. It is currently in Preclinical.
3
Indications
5
Total Trials
0
Active Trials
114
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Sulfonylureas
Eli LillyPreclinical
Active Comparator
ModernaPreclinical
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Preclinical
PEG-Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Cyclophosphamid
EEssen Biotech
Preclinical
HB-Admscs
HHope Biosciences Research Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypoxia2 trials
Intestinal Cancer1 trial
In Vivo Assessment of Hypoxia in Gastro-intestinal Cancer Using 18F-HX4-PET: an Optimization and Reproducibility Study
Completed·—·N/A·NCT01995084·32 enrolled
Pancreatic Cancer1 trial
The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome
Completed·—·N/A·NCT01989000·47 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HX4. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMaastricht Radiation Oncology